⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606525 | 1.00 | — | — | |
| SCHEMBL26279 | 0.71 | — | — | |
| SCHEMBL11917825 | 0.71 | — | — | |
| SCHEMBL31673150 | 0.71 | — | — | |
| SCHEMBL14476389 | 0.71 | — | — | |
| SCHEMBL168088 | 0.71 | — | — | |
| SCHEMBL8853006 | 0.68 | — | — | |
| Methane SCHEMBL23316999 | 0.68 | — | — | |
| Ammonia Solution, Strong SCHEMBL29099315 | 0.68 | — | — | |
| SCHEMBL28718382 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-20240122941-A1 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | NATIONAL CANCER CENTER (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| CN-116496256-A | Carbonyl bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4196125-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116261456-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| CN-115298177-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022036204-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |